Info of Speakers

Dr Moritz Kraemer

  • Branco Weiss Fellow at University of Oxford

  • Investigates the spatial dynamics of infectious diseases and their vectors

  • Tracked COVID-19 cases from Wuhan

  • Worked on establishing the Open COVID-19 Data Working Group; a system that has changed the way we tackle pandemics

Professor Graham Cooke
  • NIHR Research Professor of Infectious Diseases based within the Department of Infectious Disease at Imperial College London
  • Member of the WHO COVID-19 Guidelines Development group.
  • Led clinical development of DnaNudge: a 90 minute COVID-19 test. The UK government placed a £161m order for these test kits to be used in NHS hospital.
  • Research lead at Imperial College, participating in studies such as the REACT Study.
  • Main focus of study: precision medicine for the management of infectious diseases particularly HIV and viral hepatitis.
Professor Norbert Klein
  • Full Professor and Chair in Electromagnetic Materials and Sensors at Imperial College London
  • Main scientific activities are in the area of electromagnetic material characterization and sensor applications
  • One current focus is on graphene and related 2D materials. The other focus is on microwave-to-terahertz biosensing, in particular, blood analysis by microfluidic-resonator assemblies and single-cell detection in biological liquids
Dr Anna Blakney
  • Research Fellow at Imperial College London
  • Research focuses on optimisation of molecular RNA design and formulation for enhanced protein expression and immune response in vivo
  • Part of Professor Robin Shattock’s group who has developed a prototype vaccine for COVID-19, currently in clinical trials 

Olly Oechsle

  • Senior Engineering Manager at Benevolent AI 
  • Played pivotal role in identifying approved drugs that could tackle the coronavirus using BenevolentAi’s AI-derived knowledge graph
  • Main focus of work: developing natural language processing tools to extract information from scientific and medical literature to discover novel drugs for treatment

Sumit Popli

  • Partner, McKinsey & Company Jakarta
  • Co-leads McKinsey’s Insurance practice in Asia and Banking practice in Indonesia.
  • Serves Financial Institutions across Asian markets with deep experience in Strategy, Distribution, Risk Management, Digital & Analytics.
  • Recently, he has helped a bank build new micro, small, and medium enterprise businesses; partnering with a Thai bank to design an international expansion strategy
Simon Rasalingham
  • CEO of

  • Medica group founder, became the UK leader for remote reporting of radiological images

  • Achieved the world’s first regulatory approval for an AI technology to diagnose chest X-rays as normal

  • Diverted technologies towards aiding the COVID-19 response


Tom Dyer

  • Lead Machine Learning Engineer at

  • Research work focused on simulating protein-protein interactions within bacterial membranes and possible methods of inhibition

  • He will discuss some of the algorithmic challenges that the team has faced


Radhika Mattoo

  • Lead Sofware Engineer at
  • Provides innovative solutions to the complex problems faced in applying AI and its supporting systems to the clinical field
  • Works with both the Clinical Excellence and Operations teams to deliver stable and scalable production systems across the globe to all of’s customers
  • Radhika will be talking about how rapidly deployed into India

Michael Blaivas

  • Chief Medical Officer at EchoNous Inc
  • Expertise in medical devices and software development
  • Partnered with multi-billion dollar conglomerates
  • Recent certifications and research in Deep Learning/Artificial Intelligence in Medical Imaging

Check out some exciting start-up companies to see what’s going on right now in the MedTech world!

Working through the pandemic has brought a unique set of challenges. Yet, while trying to find solutions to working remotely, we also inadvertently improved our ways of working: We reviewed and improved our on-boarding processes, we launched our Social Connect Team where people across the business are taking more ownership in creating and sustaining our company culture. We have also increased our channels of communication, and encourage our team to share feedback more frequently to check the impact of working remotely. We ran more people-centred events to make up for the lack of everyday interactions . Events such as Munch and Learns on personal experiences and interests, along with Donut coffee breaks, which randomly pairs people for a remote coffee, have helped us focus on developing a culture where people can bring their authentic selves to work.

In terms of the our main focus before the pandemic and now, our mission has not significantly changed we know that the x-ray is one of the most commonly used diagnostic tests in the world and played a critical role in triaging patients for COVID. It was more serendipity to the fact that we had a regulatory approved algorithm that we shown generalises in three continents, that is the UK India and America. One thing that has happened as a result of COVID and lockdown is there is a huge number of patients who are not presenting due to fear into the hospital, therefore significant numbers of undiagnosed lung cancer is a serious problem not just in the UK but globally and will result in significant deaths. We have a technology that can speed up the diagnosis of lung cancer and are actively rolling this out in the NHS first. 

In terms of working life we have been all working remotely and bringing on new people into the team remotely has been very difficult. Therefore trying to take a start-up and scaling in this new normal is a challenge not just faced by us, but by many companies. We have however had some success noting that Radhika is located in New York our headquarters are in London and we’re able to deploy the world’s largest implementation of AI for covid-19 in India.




Frontline Worker Videos
Hear the perspectives from those on the frontlines of the COVID-19 response


I feel very lucky to have been asked to come back to clinical medicine (but I’m very happy to be back in Biotech!). If I’m asked to go back to the wards, I’ll be happy to do so. This is a disease that’s going to have a big effect on medicine at every level for many years. Hopefully, the things that worked well during the emergency will not be forgotten, and will be used to improve the NHS.